If there is one barrier that stops more UK patients from accessing prescribed cannabis than any other, it is not stigma, not GP reluctance, and not lack of awareness. It is cost.
Medical cannabis has been legal on prescription in the UK since November 2018. It is not available on the NHS outside a handful of exceptional cases. For the overwhelming majority of the estimated 35,000 to 45,000 patients currently prescribed, treatment is funded entirely out of pocket. So what does it actually cost?
The Initial Outlay
Most UK cannabis clinics charge an initial consultation fee of between £100 and £250. This covers a detailed assessment with a specialist clinician, review of your medical records, and — if appropriate — the issuing of your first prescription. Some clinics offer reduced rates for veterans, people on benefits, or those enrolled in patient registries like Project Twenty21.
After the initial consultation, patients typically require a follow-up appointment within the first month, costing £50 to £100, and then quarterly check-ins thereafter at similar rates. Annual consultation costs, including initial assessment, typically run between £300 and £600.
The Monthly Prescription
This is where costs vary most dramatically. A patient's monthly spend depends on their prescribed dose, the formulation (flower, oil, or both), and the specific products prescribed. Clinic data suggests the typical range is £100 to £400 per month, with most patients falling between £150 and £250.
A patient prescribed 10 grams of flower and a 10ml bottle of oil — a common starting regimen — might pay £80 to £120 for the flower and £60 to £100 for the oil, for a monthly total around £180. Higher doses and premium products push that figure higher. Some patients with complex conditions requiring high doses report monthly costs exceeding £500.
The Annual Picture
Add it all together — consultations, prescriptions, the occasional repeat prescription fee — and the typical UK patient spends between £2,000 and £4,000 per year on private cannabis treatment. That is less than many people assume, but it is still a significant sum for a treatment that many believe should be available on the NHS.
Why the NHS Won't Pay
The core obstacle is NICE guidance. In 2019, NICE recommended against the routine prescribing of cannabis-based medicinal products, citing insufficient evidence of cost-effectiveness. That recommendation, combined with the fact that most cannabis medicines remain unlicensed in the UK, has created a near-total NHS block. Fewer than five NHS prescriptions have been issued since 2018.
The paradox is visible to anyone looking: a treatment that tens of thousands of patients are paying for privately, that clinicians are prescribing based on real-world evidence, and that patients report as effective — but that the state will not fund because the evidence base does not meet a threshold designed for pharmaceutical drugs with billion-pound development budgets.
Where the System Goes From Here
The cost conversation is not static. As the patient population grows and more products enter the market, prices are falling — slowly. Some clinics now offer subscription models. Others are investing in real-world evidence registries designed to meet the evidentiary bar NICE requires. The goal, however distant, is NHS access. Until then, patients pay — and the system watches.
